Daily FNArena News - Small Caps

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | Technicals | Treasure Chest

Previous Stories

Capitol Health Maintains Robust Outlook

Aug 13 2015

Diagnostic imaging operator, Capitol Health, is in robust form heading into FY16, supported by demographics and low competitive tension.


Lingering Concerns For Greencross

Aug 12 2015

Greencross has a dominant position in the pet care market and, whlie brokers are largely positive, there are some lingering concerns from the FY15 results.


OzForex Takes On The World

Aug 06 2015

OzForex Group has outlined a new strategy to rapidly accelerate revenue growth and expand its presence in the money transfer business, and brokers are prepared to back it.


Substantial Potential Flagged For Karoon Gas

Aug 06 2015

Karoon Gas is an early mover on prospective oil and gas exploration and Morgans initiates coverage on the stock.


Stellar Performance Expected From amaysim

Aug 04 2015

Amaysim has recently listed on ASX and two brokers initiate coverage of the stock, expecting strong growth going forward.


Brokers Highlight Potential In Adairs

Aug 03 2015

Home furnishing retailer Adairs is a beneficiary of the strong housing cycle in Australia and several brokers have initiated coverage of the stock.


Capitol Health On A Strong Growth Path

Jul 30 2015

Capitol Health is on a strong growth path, supported by acquisitions and an increasingly preventative approach to medicine.


Senex Energy Prioritises Gas Assets

Jul 29 2015

In the face of weak oil prices, Senex Energy is reviewing its capital allocation and prioritising its gas assets.


SpeedCast Ramps Up Service

Jul 23 2015

Brokers believe SpeedCast International has made a sound purchase of two teleports, allowing for traffic consolidation and service expansion.


Impedimed Prospects Boosted By NCCN Advice

Jul 22 2015

A decision by the US National Comprehensive Cancer Network to recommend breast cancer patients be monitored for lymphoedema is considered a boost to Impedimed’s prospects.



Analyse The Market From A Different Angle